Eclipsebio acquired Terrain Bio to combine Terrain’s machine learning RNA analytics with Eclipsebio’s sequencing-first validation platform, aiming to create an end‑to‑end RNA therapeutic design, manufacturing, and validation stack. The deal is pitched to accelerate iterative RNA construct design and to deliver actionable manufacturing insights for RNA drug developers. Eclipsebio will integrate Terrain’s AI capabilities to optimize construct design upstream and use deep sequencing analytics to validate translation, structure and impurity profiles. The acquisition reflects consolidation in the emergent RNA tools category where design AI and high‑resolution QC are converging into unified commercial offerings.